Trials
1 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)”In the company’s words, NCT06798727 on ClinicalTrials.gov
- Tested for
- Knee Osteoarthritis
- Main trialPhase 2
- “This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.”In the company’s words, NCT06798727 on ClinicalTrials.gov
Other drugs for Knee Osteoarthritis
- JointstemR-Bio · Phase 3
- DiacereinTRB Chemedica · Phase 3
- Mesenchymal Stem CellsWuxi Cellular Biopharmaceutical Group Ltd. · Phase 3
- PTP-01Doron Therapeutics Inc. · Phase 3
- Sodium hyaluronateIBSA Institut Biochimique SA · Phase 3
- Pentosan Polysulfate SodiumParadigm Biopharmaceuticals Ltd. · Phase 3
Coming up1
- 20 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 20 Mar 2027 | Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control | |
| Phase 2Completed | 17 Oct 2023 | Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis | |
| Phase 1Completed | 12 Nov 2020 | Evaluate Safety and Explore Efficacy of SMUP-IA-01 in Patients With Knee Osteoarthritis | |
| Phase 1Unknown | Dec 2025 | Follow-up Safety and Efficacy Evaluation on Subjects Who Completed Phase I Clinical Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026